• BKT140 (BL-8040): Applied CXCR4 Antagonism in Oncology Resea

  2026-05-28

  BKT140 (BL-8040) sets a new standard in targeted CXCR4 inhibition for oncology and stem cell workflows, enabling robust chemotaxis suppression and apoptosis induction. This article delivers stepwise protocols, troubleshooting guidance, and translational insights that optimize BKT140's power in tumor microenvironment and hematopoietic assays.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Canc

  2026-05-28

  The referenced study demonstrates that anlotinib hydrochloride is a highly potent and selective VEGFR2 inhibitor, with strong anti-angiogenic activity in preclinical cancer models. Its superior selectivity and in vivo efficacy highlight its value for translational cancer research and targeted anti-angiogenic strategies.

• UBE2F-SAG–Mediated RHEB Neddylation Drives mTORC1 in HCC

  2026-05-27

  This study demonstrates that RHEB is a direct substrate for neddylation by the UBE2F-SAG axis, which enhances mTORC1 activity and exacerbates liver tumorigenesis. These findings reveal a new regulatory mechanism for mTORC1 signaling in hepatocellular carcinoma and suggest novel targets for metabolic liver disease intervention.

• Caspofungin: Advanced Mechanisms and Protocols in Antifungal

  2026-05-27

  Explore Caspofungin, a leading lipopeptide antifungal drug, and its advanced role in targeting β-(1,3)-D-glucan biosynthesis for Candida research. This article delivers scientific insight and practical guidance for assay optimization, resistance modeling, and translational antifungal strategies.

• QRICH1 Drives HBV-Induced HMGB1 Secretion and Hepatic Fibros

  2026-05-26

  This study reveals that QRICH1, a key effector of endoplasmic reticulum (ER) stress, enhances hepatitis B virus (HBV)-induced translocation and secretion of HMGB1 in hepatocytes, thereby promoting hepatic fibrosis. These findings clarify the molecular interplay between ER stress, QRICH1, and HMGB1 during chronic HBV infection and suggest new mechanistic links relevant for liver disease research.

• Doxycycline in Precision Vascular Research: Mechanisms and I

  2026-05-26

  Explore how Doxycycline, a tetracycline antibiotic, is transforming vascular and cancer research through its unique metalloproteinase inhibition and precision delivery strategies. This article offers new scientific insights and practical protocols, advancing beyond previous reviews.

• hCG Regulates CXCL10 via H3K27 Methylation in Human Decidua

  2026-05-25

  This study uncovers how human chorionic gonadotropin (hCG) modulates immune cell recruitment in early pregnancy by suppressing CXCL10 expression through EZH2-mediated H3K27 trimethylation. The findings reveal an epigenetic mechanism at the maternal-fetal interface, offering insight into immune tolerance crucial for successful implantation and placental development.

• Protease and Phosphatase Inhibitor Cocktail: Advanced Strate

  2026-05-25

  Discover how the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) elevates protein extraction workflows in immunology and sepsis models. This article explores advanced preservation of post-translational modifications and offers insights beyond standard protocols.

• CTCF Safeguards Centromere Function and Mitotic Precision

  2026-05-24

  This study uncovers CTCF as a crucial factor for centromere maintenance and accurate mitotic division in human cells. Using rapid protein depletion, the authors demonstrate that CTCF loss leads to disrupted chromosome alignment and altered nuclear morphology, providing mechanistic insights valuable for cell cycle and cancer research.

• Preclinical Evaluation of Anlotinib: Potent VEGFR2 Inhibitio

  2026-05-23

  This article analyzes the preclinical characterization of anlotinib hydrochloride as a highly potent and selective multi-target tyrosine kinase inhibitor, emphasizing its efficacy in inhibiting VEGFR2-mediated angiogenesis. The findings highlight its mechanistic specificity, broad in vivo antitumor activity, and practical implications for cancer research workflows.

• Viperin Disrupts Coronavirus Replication via nsp8 Targeting

  2026-05-22

  This study uncovers a conserved antiviral mechanism in which Viperin inhibits coronavirus replication by binding to non-structural protein 8 (nsp8), disrupting replication-transcription complex (RTC) assembly and reducing RNA polymerase activity. These insights highlight both ddhCTP-dependent and -independent pathways, informing the use of nucleotide analogs and guiding next-generation antiviral strategies.

• Flumequine: Precision DNA Topoisomerase II Inhibitor Workflo

  2026-05-22

  Flumequine delivers robust, reproducible DNA topoisomerase II inhibition, making it indispensable for DNA replication research and advanced cancer drug-response assays. This article translates bench-validated protocols, optimization strategies, and troubleshooting insights into actionable, high-impact workflows for researchers.

• CTCF is Essential for Centromere Maintenance and Mitotic Fid

  2026-05-21

  This study demonstrates that CTCF, beyond its known interphase roles, is required for maintaining centromere structure and ensuring accurate chromosome segregation during mitosis. Rapid CTCF depletion disrupts centromere function, chromosome alignment, and post-mitotic nuclear morphology, revealing new mechanistic insights relevant for cancer and cell cycle research.

• CHIR-99021 (CT99021): Driving Precision in Stem Cell Differe

  2026-05-21

  CHIR-99021 (CT99021) stands out as a gold-standard GSK-3 inhibitor for precise stem cell fate control, notably enabling efficient, serum-free differentiation workflows. Recent reference studies highlight its critical role in orchestrating Wnt/β-catenin pathway modulation for reproducible and scalable generation of functional cell types.

• hsa_circ_0001944 Modulates FXR/TLR4-Ferroptosis Axis in NiON

  2026-05-20

  This study reveals how hsa_circ_0001944 regulates the FXR/TLR4 signaling pathway and ferroptosis to mitigate collagen deposition in LX-2 cells exposed to nickel oxide nanoparticles. The findings clarify molecular mechanisms underlying nanoparticle-induced liver fibrosis and offer new cellular and molecular targets for antifibrotic research.

15486 records 1/1033 page Next 12345 下5页 Last page